The Transdermal Delivery System of Monoamine Oxidase Inhibitors

Chad M. VanDenBerg, PharmD, BCPP

Monoamine oxidase inhibitors (MAOIs) were once widely used as effective treatments for major depressive disorder, particularly for patients with atypical or treatment-resistant depression. Today, MAOIs have largely been replaced by newer antidepressants because of concerns over potential serious side effects due to their mechanism of action. Monoamine oxidase (MAO) is an enzyme that metabolizes serotonin, norepinephrine, and dopamine, the neurotransmitters that are most associated with depression; inhibiting MAO, therefore, makes more of these neurotransmitters available for synaptic action. However, MAO also metabolizes tyramine, a trace amine found in some foods that acts as a sympathomimetic. Allowing excess tyramine to accumulate via MAO inhibition can result in hypertensive crisis due to the release of norepinephrine; therefore, patients taking an MAOI have had to follow dietary restrictions to avoid tyramine-rich foods. Hypertensive crisis may also be precipitated by using MAOIs in conjunction with other drugs that have vasoconstrictive properties, that act as sympathomimetics, or that inhibit the reuptake of norepinephrine. Serotonin syndrome is another serious adverse effect that can potentially occur when using an MAOI with another drug that inhibits the reuptake of serotonin. In this article, the mechanism of action of MAOIs is reviewed, along with that of a newer MAOI formulation that lessens the need for dietary restrictions and has a greater safety and tolerability profile than the older oral formulations.

MAOI MECHANISM OF ACTION

The pathophysiology of depression has yet to be fully understood, but all pharmacotherapies for the disorder are based on increasing the synaptic action of one or more of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. The MAOIs inhibit monoamine oxidase (MAO), a mitochondrial enzyme that acts as a catalyst for converting biogenic amines to their corresponding aldehydes. The MAO enzyme oxidatively deaminates and inactivates excess neurotransmitter molecules; therefore, inhibiting MAO activity by deactivating the enzyme allows serotonin, norepinephrine, and dopamine to accumulate, increasing their availability for synaptic action. Originally, this action was thought to be the basis for the antidepressant action of MAOIs, but one hypothesis proposes secondary adaptive mechanisms, such as downregulation of monoamine receptors and the elevation of other trace amines, as possible factors in the antidepressant effect. Although MAOIs increase the availability of monoamines almost immediately, the secondary effects occur after chronic administration of the medication over several weeks, which coincides with the delayed onset of antidepressant effect.

MAO Subtypes

Two isoenzymes of MAO have been identified: MAO-A and MAO-B. Both are found in the central nervous system (CNS) and in the intestine and liver, but they have different substrates and different relative distributions. MAO-A is mainly found in the brain and intestine and is present in serotonin, dopamine, and norepinephrine neurons. In the brain, MAO-A preferentially metabolizes serotonin and norepinephrine, and in the intestine, MAO-A catabolizes amines absorbed into the gastrointestinal (GI) tract, including tyramine. The main substrates for MAO-B, which is found in brain regions rich in serotonergic neurons and in platelets and other tissues, are β-phenylethylamine, dopamine, and tyramine. MAO-B preferentially metabolizes trace amines such as 2-phenylethylamine. Both MAO-A and MAO-B metabolize dopamine.
MAO is an enzyme that metabolizes serotonin, norepinephrine, and dopamine; inhibiting MAO allows these neurotransmitters to accumulate in the synaptic cleft.

MAOIs have potentially serious side effects, such as hypertensive crisis and serotonin syndrome, due to diet and drug interactions.

To avoid these adverse effects, patients should be educated regarding dietary restrictions and drug interactions.

A transdermal MAOI formulation with a greater tolerability and safety profile than oral MAOIs is available, which, at the minimum effective dosage, avoids the need for dietary restrictions.

Inhibition of MAO-A increases the levels of serotonin and norepinephrine and, to a lesser extent, dopamine, as dopamine will still be metabolized by MAO-B (Figure 1). Inhibiting MAO-B has little effect on serotonin and norepinephrine levels, and dopamine levels will not rise substantially due to continued metabolism by MAO-A. MAO-A preferentially metabolizes all 3 of the monoamines most associated with depression, and inhibition of MAO-A in the brain is needed for an antidepressant effect. However, inhibiting both MAO-A and MAO-B leads to a greater increase in all 3 neurotransmitters than inhibition of either alone.

MAOIs can be either nonselective or selective. Nonselective MAOIs inhibit both isoenzymes, whereas selective MAOIs inhibit either MAO-A or MAO-B. The classic oral MAOIs approved to treat depression in the United States (isocarboxazid, phenelzine, and tranylcypromine) are all nonselective. Oral selegiline is a selective inhibitor of MAO-B and is approved at low doses (10 mg/d) as an adjunct to carbidopa/levodopa to treat Parkinson's disease. Even at doses high enough to induce an antidepressant effect (30 to 60 mg/d), oral selegiline loses its selectivity and inhibits both MAO-A and MAO-B.

All MAOIs approved to treat depression in the United States are irreversible, meaning they bind to MAO for the life of the enzyme. Once the medication is stopped, a period of 7 to 10 days is required for new MAO enzyme to be generated and enzymatic activity to resume.

Adverse Effects and Mechanism of Action

The most common early side effects of oral MAOIs include insomnia, sedation, orthostatic hypotension, dizziness, and nausea. Later side effects reported for MAOIs include weight gain, edema, muscle pain, myoclonus, paresthesia, and sexual dysfunction. The most serious adverse effects associated with MAOIs, however, are due to food and drug interactions.

Food interactions. Tyramine is a trace amine, found in many foods, that acts as an indirect sympathomimetic. MAO-A metabolizes dietary tyramine in the GI system and liver, which restricts the uptake of tyramine into the circulatory system. Irreversible inhibition of intestinal MAO-A, via oral delivery of an MAOI, can therefore lead to serious interactions with foods containing high levels of tyramine.

Normally, MAO-A in the intestinal wall and in the liver can metabolize up to 400 mg of ingested tyramine. When MAO-A is inhibited in the gut, as little as 10 mg of ingested tyramine can cause an excessive amount to enter the bloodstream, where it triggers the release of norepinephrine from sympathetic nerve terminals. Excess norepinephrine causes a rapid and sometimes severe increase in blood pressure that can lead to hypertensive crisis, possibly resulting in stroke or even death. Thus, patients taking irreversible, nonselective MAO inhibitors must follow dietary restrictions that limit tyramine intake.

Reversible inhibitors of MAO-A (RIMAs) have been developed in an effort to avoid the tyramine reaction. With these medications, when tyramine is ingested and absorbed in the gut in large enough amounts to increase the release of norepinephrine, the accumulation of norepinephrine displaces the RIMA from the active site on the MAO-A enzyme, allowing the norepinephrine to be metabolized. Dietary restrictions are unnecessary with RIMAs. As tyramine does not cross the blood-brain barrier, MAO-A in the brain will continue to be inhibited, maintaining the antidepressant effect. The MAO-A selective RIMA moclobemide is available throughout much of the world but is not approved in the United States.

Drug interactions. The amount of norepinephrine potentiated by MAOIs alone is not great enough to elevate blood pressure in the absence of tyramine ingestion. However, MAOIs should not be used in combination with other adrenergic medications, including some decongestants, stimulants such as methylphenidate and amphetamines, opioids or pain medications that contain sympathomimetic vasoconstrictors, and antidepressants or appetite suppressants with norepinephrine uptake inhibition, as hypertensive crisis can result.

Combining MAOIs with medications that inhibit serotonin reuptake (including other antidepressants, certain analgesic agents, and the antitussive agent dextromethorphan) can cause serotonin syndrome, a potentially lethal condition caused by the accumulation of excessive serotonin. When switching a patient to or from an MAOI, a washout period of about 2 weeks is recommended; switching from fluoxetine, however, requires a washout period of 5 weeks due to its long half-life.

TRANSDERMAL DELIVERY SYSTEM FOR SELEGILINE

Although simplified over the years, the dietary restrictions that accompany MAOI use have been perceived by patients and clinicians as difficult to manage. One effort to improve the safety of MAOIs and limit or avoid the need for dietary restrictions was the development of the selegiline transdermal system (STS). With the STS, the drug is...
Transdermal Delivery of MAOIs

Delivered in a controlled manner over 24 hours via the once-daily application of a matrix-type patch. By bypassing the GI tract, the transdermal preparation of selegiline avoids the complete inhibition of MAO-A in the gut that occurs with oral MAOIs.

Pharmacokinetics

The physiochemical properties of selegiline (eg, low molecular weight, high lipid solubility) make it well-suited for transdermal delivery. Selegiline is a weak base with a molecular weight of 187.3, a pKa of 7.5, and a calculated octanol/water partition coefficient of 3.4. Delivering a highly lipid-soluble compound such as selegiline transdermally allows it to rapidly penetrate cell membranes and quickly reach target sites in the CNS. Upon application of the patch, about 25% to 30%, on average, of the selegiline content is delivered systemically over 24 hours, and steady-state plasma concentrations are achieved within 5 days of daily dosing. Gender does not affect the pharmacokinetics or metabolism of transdermally delivered selegiline.
Table 1 summarizes the pharmacokinetics of oral selegiline and the STS.18

A randomized, open-label study16 demonstrated that transdermal selegiline delivers a higher plasma concentration of drug to the CNS over a longer period of time, and with a lower dosage, than does oral selegiline. The greater bioavailability of 6 mg of transdermal selegiline (73.4%) versus 10 mg of oral selegiline (4.4%) is due to the avoidance of the extremely high first-pass metabolism that occurs with the oral medication in the GI system and liver before entering the circulatory system.16 In addition, transdermal selegiline maintains a sustained plasma concentration during the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication maintains a sustained plasma concentration during entering the circulatory system.16 In addition, transdermal selegiline maintains a sustained plasma concentration during the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because MAO-A is largely unaffected in the gut by the 24-hour application period, whereas the oral medication plasma concentration peaks within 1 hour and then declines rapidly. Because...[the remainder of the paragraph continues]

Both oral and transdermal selegiline are metabolized through multiple CYP450 isoenzymes and form, in order, the metabolites N-desmethylselegiline, l-methamphetamine, and l-tryptamine.16 However, metabolite levels, which may be associated with neurotoxicity, are greatly reduced with transdermal delivery (see Table 1).18,20

Pharmacodynamics

Transdermal selegiline must be administered at doses high enough to lose its selectivity for MAO-B in order to have an antidepressant effect. While oral selegiline inhibits MAO-A activity in the brain and duodenum to a similar extent, to avoid reactions to dietary tyramine, the transdermal delivery system preferentially targets MAO-A activity in the brain over peripheral activity. Transdermal selegiline ID50 values for inhibition of brain MAO-A activity are 7.5 times lower than ID50 values for inhibition of intestinal MAO-A activity.21 This means that the antidepressant effect, via inhibition of MAO-A in the brain, can occur with a significantly lower potential for tyramine reactions due to inhibition of MAO-A in the gut. Based on route of delivery and avoidance of the first-pass effect, transdermally delivered selegiline is 6 to 8 times more potent for inhibiting brain MAO-A activity than orally delivered selegiline. Therefore, a lower dose is needed to produce an antidepressant effect.

Animal studies18 show that STS doses that inhibit more than 90% of the activity of both MAO-A and MAO-B in the brain have a maximal inhibition of 40% of MAO-A and 70% to 75% of MAO-B activity in GI tissue. Doses that inhibit brain MAO-A by 55% to 60% and brain MAO-B by 85% to 90% show no inhibition of GI MAO-A activity and show only 40% to 60% inhibition of GI MAO-B activity. In these studies, higher doses lost their selectivity for inhibiting MAO-B in the brain but not in GI tissue.

Safety Profile

In placebo-controlled trials22,23 of STS for treatment of acute depression, the tolerability profile of STS was similar to that of placebo except for application site reactions. No significant differences between the treatment groups and the placebo groups were noted for adverse effects for cardiovascular, nervous, digestive, respiratory, urogenital, or musculoskeletal systems or for sexual function. A 52-week study24 that assessed maintenance treatment with STS also reported a safety profile similar to that of placebo except for application site reactions.

Transdermal selegiline is classified as a nonallergen; application site reactions are similar to those of other transdermally delivered medications and probably due to the adhesive used in the patch.25 Application site reactions are generally a form of irritant contact dermatitis (rather than allergic contact dermatitis) and are mild to moderate, transient in nature, and resolve spontaneously after patch removal.26 Skin reactions can be minimized by rotating the patch site, carefully removing the patch and then washing the site with warm soapy water, and using moisturizers and topical corticosteroids.

The available STS patches deliver 6 mg, 9 mg, or 12 mg of medication per 24 hours, and no hypertensive crises have been reported at any dose of the patch. A study19 of tyramine pressor sensitivity found no significant effects for the minimum effective dose (6 mg/24 h) after 33 days of treatment. Dietary restrictions are not necessary at the 6 mg/24 hours dose but are recommended at higher doses due to a lack of safety data.

Table 1. Pharmacokinetic Profiles of Oral Versus Transdermal Selegilinea,b

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Oral Selegiline (10 mg)</th>
<th>STS (20 mg/20 cm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Half-life</td>
<td>9.7 h</td>
<td>20.1 h</td>
</tr>
<tr>
<td>Metabolisms</td>
<td>CYP450 2A6, 2B6, 3A4/5, 2C9, 2D6</td>
<td>CYP450 2A6, 2B6, 3A4/5, 2C9, 2D6</td>
</tr>
<tr>
<td>Time to mean peak plasma concentrations</td>
<td>0.9 h</td>
<td>18.4 h</td>
</tr>
<tr>
<td>Metabolites (AUCinf M/P)</td>
<td>MET/DES/AMT (903.1/861.3/320.6)</td>
<td>MET/DES/AMT (2.4/0.6/1.0)</td>
</tr>
<tr>
<td>Plasma levels</td>
<td>Variable peak-trough fluctuation</td>
<td>Minimal peak-trough fluctuation</td>
</tr>
<tr>
<td>Route of administration</td>
<td>Oral</td>
<td>Skin</td>
</tr>
<tr>
<td>Maximum plasma concentrations (pg/mL)</td>
<td>2.222</td>
<td>2.162</td>
</tr>
<tr>
<td>First-pass metabolism</td>
<td>High</td>
<td>None</td>
</tr>
<tr>
<td>%Fe</td>
<td>0.02</td>
<td>0.07</td>
</tr>
<tr>
<td>Intestinal inhibition of MAO-A</td>
<td>Definite beyond 10 mg/d</td>
<td>Less likely at approved dose</td>
</tr>
<tr>
<td>Bioavailability</td>
<td>4%</td>
<td>75%</td>
</tr>
</tbody>
</table>

*Reprinted with permission from Pae et al.18

aDietary modifications were not necessary for patients given STS at 6 mg/24 hours, while patients given STS at 9 mg/24 hours or 12 mg/24 hours required some dietary modification.

bThe doses of STS that produced the maximum MAO-A inhibition in the brain inhibited MAO-A in the gastrointestinal tissue by only 30% to 40%.

Abbreviations: %Fe = fraction excreted in the urine unchanged, AMT = l-amphetamine, AUCinf MP = ratio of the metabolite to the parent compound area under the concentration-time curve from time zero extrapolated to infinity, CYP = cytochrome, DES = N-desmethylselegiline, MAO = monoamine oxidase, MET = l-methamphetamine, STS = selegiline transdermal system.
Although the STS reduces the risk of food interactions, it does not protect against potential hypertensive crisis and serotonin syndrome due to drug interactions. The same precautions against drug interactions should be taken when using STS as when using other MAOIs.

### Efficacy for Major Depressive Disorder

Three placebo-controlled trials demonstrated efficacy for STS over placebo for the acute treatment of depression (Table 2). In the first trial, patients were randomly assigned to take either 6 mg/24 hours STS or placebo for 6 weeks. Patients in the STS group experienced significantly better outcomes on all primary measures. In the second trial, 145 patients received STS 6 mg/24 hours and 144 patients received the placebo patch for 8 weeks. This trial showed a modest but significant benefit for the STS over placebo. A third placebo-controlled study investigated the efficacy of STS administered in a dose range (6 mg/24 h to 12 mg/24 h) for 8 weeks and showed antidepressant efficacy over placebo across the dose range for both primary and secondary outcome measures.

A 52-week trial investigated relapse rates for patients randomly assigned to take STS or placebo after responding to 10 weeks of acute treatment with STS 6 mg/24 hours. Compared with patients receiving placebo, significantly fewer patients receiving STS experienced relapse ($P = .0025$), and patients receiving STS experienced a significantly longer time to relapse ($P = .0048$).

### Advantages of Transdermal Delivery

Skin patches have become fairly familiar to patients over the past few decades, as they have been used in the treatment of various illnesses including motion sickness, Alzheimer's disease, restless legs syndrome, Parkinson's disease, pain from postherpetic neuralgia, smoking addiction, attention-deficit/hyperactivity disorder, and angina. Patches are also used for contraception and hormone replacement. The STS uses a matrix-type patch, which has several advantages over the older reservoir-type patch. With many reservoir patches, the drug is contained in an alcohol solution, which irritates the skin. Matrix patches are smaller and thinner, adhere better to the skin, and are generally better tolerated than reservoir patches.

With a transdermal patch, some of the side effects that occur when the same drug is delivered orally can be avoided because the drug is delivered directly into the circulatory system. The transdermal patch avoids certain side effects created due to first-pass metabolism in the intestine and liver. The patch also maintains steady plasma drug levels, thereby reducing tolerability problems that are associated with fluctuations in plasma concentrations. The reduction in adverse effects may help patients to more easily reach and maintain therapeutic levels of the drug, which should provide greater efficacy and, in turn, increase treatment adherence.

Another advantage of the patch delivery system is ease of use; patches are applied once a day, simplifying the treatment regimen for those taking multiple daily doses of oral formulations, and are a visual reminder that treatment has been administered. Transdermal delivery can also be helpful for patients with certain medical conditions, such as swallowing difficulties.

### CONCLUSION

Classic MAOIs are effective for depression but have serious potential side effects, including hypertensive crisis due to food interactions.
to either ingestion of dietary tyramine or drug interactions and serotonin syndrome due to drug interactions. A modified diet that restricts tyramine intake is necessary with the oral MAOIs that are available in the United States; however, a transdermal formulation for selegiline has lessened the need for these restrictions. Avoiding other medications that boost norepinephrine or serotonin levels can prevent hypertensive crisis and serotonin syndrome due to drug interactions.

With a better safety and tolerability profile than that of oral MAOIs, STS offers another option for treating depression, particularly for patients with atypical or treatment-resistant depression.

**Drug names**
- carbidopa/levodopa (Parcopa, Sinemet, and others)
- fluoxetine (Prozac and others)
- isocarboxazid (Marplan)
- methylphenidate (Focalin, Daytrana, and others)
- phenelzine (Nardil and others)
- selegiline oral formulation (Eldepryl, Zelapar, and others)
- selegiline transdermal system (EMSAM), tranylcypromine (Parnate and others)

**Disclosure of off-label usage:** The author has determined that, to the best of his knowledge, oral selegiline and moclobemide are not approved by the US Food and Drug Administration for the treatment of depression.

**REFERENCES**